Gelonghui, May 21丨Bailey Tianheng (688506.SH) announced that BL-B01D1 is a globally exclusive dual-antibody ADC drug independently developed by the company that can target EGFR and HER3 at the same time in clinical trials. Recently, the clinical study of BL-B01D1 monotherapy for HR+HER2-breast cancer has entered the phase III clinical trial stage and completed the enrollment of the first patient. Up to now, the domestic Phase III registered clinical trial of BL-B01D1 as a single drug for the treatment of terminal nasopharyngeal cancer and second-line esophageal squamous cell carcinoma is currently in the phase III registration phase of subjects.
百利天恒(688506.SH)：注射用BL-B01D1用于局部晚期、复发或转移性HR+HER2-乳腺癌III期临床试验完成首例受试者入组
Baili Tianheng (688506.SH): BL-B01D1 for injectable locally advanced, recurrent, or metastatic HR+HER2-breast cancer phase III clinical trial completed the first patient enrollment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.